Combination therapy of Eicosapentaenoic acid and pitavastatin for Regression of coronary plaque evaluated by integrated backscatter intravascular ultrasonography; CHERRY study

Combination therapy of Eicosapentaenoic acid and pitavastatin for Regression of coronary plaque evaluated by integrated backscatter intravascular ultrasonography; CHERRY study - EPA and pitavastatin therapy for coronary plaque

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002815

Enrollment

200

Registered

2009-11-30

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable angina or acute coronary syndrome

Interventions

pitavastatin pitavastatin and EPA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stable angina or acute coronary syndrome received PCI whose LDL-cholesterol level is above 140 mg/dL or eligible for the study determined by physicians.

Exclusion criteria

Exclusion criteria: 1) Patients whose target lesion site is coronary bypass graft. 2) Patients who have undergone previous PCI on the lesion site where the evaluation of integrated backscatter intravascular ultrasonography is planned. 3) Patients who might undergo PCI on the lesion site where the evaluation of integrated backscatter intravascular ultrasonography is planned. 4) Patients with familial hypercholesterolemia. 5) Patients with a past history of allergy to EPA and/or pitavastatin. 6) Patients with hepatic dysfunction (ALT 100 IU/L or more) and/or biliary obstruction. 7) Patients with renal dysfunction (serum creatinine 2.0 mg/dL or more) or undergoing dialysis. 8) Patients ineligible for the study determined by physicians.

Design outcomes

Secondary

Measure	Time frame
1) Changes in volume and minimum intravascular lumen diameter of target coronary plaque. 2) Changes in TC, LDL-C, TG, HDL-C, MDA-LDL, RLP-C, Lp(a) and apoprotein (Apo A-I, Apo B, Apo E). 3) Changes in EPA/arachidonic acid. 4) Changes in hs-CRP. 5) Changes in volume and minimum intravascular lumen diameter of coronary plaque undergone PCI. 6) Changes in % stenosis. 7) Incidence of major adverse cardiovascular events (MACE; defined as cardiac death, nonfatal myocardial infarction, PCI or coronary artery bypass grafting)	—

Measure

Time frame

1) Changes in volume and minimum intravascular lumen diameter of target coronary plaque. 2) Changes in TC, LDL-C, TG, HDL-C, MDA-LDL, RLP-C, Lp(a) and apoprotein (Apo A-I, Apo B, Apo E). 3) Changes in EPA/arachidonic acid. 4) Changes in hs-CRP. 5) Changes in volume and minimum intravascular lumen diameter of coronary plaque undergone PCI. 6) Changes in % stenosis. 7) Incidence of major adverse cardiovascular events (MACE; defined as cardiac death, nonfatal myocardial infarction, PCI or coronary artery bypass grafting)

—

Primary

Measure	Time frame
Change of tissue characteristics in coronary plaque evaluated by integrated backscatter intravascular ultrasonography	—

Countries

Japan

Contacts

Public ContactTetsu Watanabe

Yamagata University School of Medicine Department of Cardiology, Pulmonology, and Nephrology

tewatana@med.id.yamagata-u.ac.jp023-628-5302

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026